Table 1 Baseline data
Subcutaneous group (n = 129) | Intramuscular group (n = 100) | Refuse to participate (n = 132) | Lost of follow-up (n = 22) | |
|---|---|---|---|---|
Mean age (SD), years | 73,5 (9,7) | 73,7 (9,2) | 73,5 (11,0) | 66,2 (17,1) |
Men, n (%) | 81 (62,8%) | 56 (56,0%) | 78 (59,1%) | 12 (54,5%) |
Therapeutical objective, n (%) | ||||
INR 2,0 – 3,0 | 116 (89,9%) | 94 (94,0) | 128 (97,0%) | 21 (95,5%) |
INR 2,5 – 3,5 | 13 (10,1%) | 6 (6,0%) | 4 (3,0%) | 1 (4,5%) |
Mean INR (SD) | 2,25 (0,59) | 2,37 (0,56) | 2,40 (0,61) | |
INR, n (%) | ||||
INR < 2 | 42 (32,6%) | 23 (23,0%) | 5 (22,7%) | |
INR >= 2 & < 3 | 73 (56,6%) | 63 (63,0%) | 13 (59,1%) | |
INR >= 3 & <= 4 | 14 (10,9%) | 14 (14,0%) | 4 (18,2%) | |
Mean arm circumference (SD), cm | 32,1 (3,5) | 31,8 (4,1) | 32,5 (4,2) |